For decades, breastfeeding was considered an absolute contraindication for women living with HIV due to the risk of transmitting the virus to their infants through breast milk. Still, recent scientific consensus has shifted, recognizing that with effective antiretroviral treatment and sustained viral suppression, the risk of perinatal HIV transmission during breastfeeding is extremely low. This evolving understanding marks a significant advancement in maternal and child health, offering new possibilities for mothers living with HIV who wish to breastfeed while safeguarding their babies’ health.
The change in guidance stems from robust evidence showing that when mothers living with HIV maintain an undetectable viral load through consistent antiretroviral therapy (ART), the likelihood of transmitting the virus to their babies via breastfeeding is reduced to negligible levels. According to HIV.gov, viral suppression is defined as having fewer than 200 copies of HIV per milliliter of blood, and when achieved and maintained, it allows the virus to become undetectable in standard laboratory tests. This state, known as an undetectable viral load, not only preserves the mother’s health but also prevents sexual transmission of HIV—a principle widely recognized as “Undetectable = Untransmittable” or U=U.
Extending this principle to infant feeding, the World Health Organization (WHO) has updated its recommendations to support breastfeeding among women living with HIV in settings where maternal ART is accessible and adherence is supported. A WHO document presented at the 12th International AIDS Society Conference on HIV Science (IAS 2023) in Brisbane, Australia, affirmed that the risk of HIV transmission when viral load is suppressed—even if detectable at very low levels—is “practically zero or negligible.” The report emphasized that in resource-limited settings, dried blood spot testing can help overcome logistical barriers to viral load monitoring, although the clinical threshold for detecting unsuppressed viral load in such tests is approximately 1,000 copies/mL due to smaller sample volumes.
These findings are reinforced by guidance from MedlinePlus, which states that HIV medications reduce the viral load in the body to very low levels, with the goal of making it undetectable by standard lab tests. For pregnant and breastfeeding individuals, achieving and maintaining an undetectable viral load is considered the best way to protect both maternal and infant health. The site notes that most HIV medications are safe to use during pregnancy and breastfeeding and do not increase the risk of birth defects, though individuals should consult their healthcare providers to determine the most appropriate treatment regimen.
The shift in policy reflects a broader movement toward empowering women living with HIV to produce informed choices about infant feeding without facing undue stigma or restriction. Previously, formula feeding was often recommended as the sole safe option to prevent mother-to-child transmission, particularly in high-resource settings where clean water and formula are reliably available. However, in low- and middle-income countries, formula feeding carries its own risks, including malnutrition and diarrheal disease due to unsafe water preparation. By supporting breastfeeding under conditions of viral suppression, health authorities aim to balance HIV prevention with optimal infant nutrition and survival outcomes.
Healthcare providers now play a critical role in guiding mothers living with HIV through infant feeding decisions. This includes initiating ART as early as possible, monitoring viral load regularly, and providing support for medication adherence. For mothers who are newly starting ART or have inconsistent viral suppression, more sensitive viral load testing may be recommended, and infant prophylaxis with antiretroviral drugs may be advised as an added preventive measure during the breastfeeding period.
Despite the progress, challenges remain in ensuring equitable access to ART and viral load testing globally. Disparities in healthcare infrastructure, particularly in rural and underserved communities, can hinder consistent monitoring and treatment adherence. Social stigma surrounding HIV may discourage some women from disclosing their status or seeking care, potentially affecting their ability to maintain viral suppression. Addressing these barriers requires integrated approaches that combine medical care, community education, and policy support.
Ongoing research continues to refine understanding of HIV transmission risks during breastfeeding. Studies are examining the impact of different ART regimens, the duration of breastfeeding, and the role of maternal immune factors in reducing transmission. Long-term follow-up of children exposed to HIV but not infected is also informing best practices for pediatric care and developmental monitoring.
As of now, no new global guidelines on HIV and infant feeding have been formally announced beyond the WHO’s 2023 position statement. Individuals seeking the most current recommendations are encouraged to consult trusted sources such as HIV.gov, the World Health Organization, and national public health agencies. Healthcare providers remain the best source of personalized advice tailored to individual health circumstances and local context.
This evolving perspective on breastfeeding and HIV underscores the power of scientific advancement to transform public health policy and improve quality of life. By grounding recommendations in evidence and supporting maternal autonomy, health systems can better serve families affected by HIV while promoting the well-being of both mothers and children.
To stay informed about updates in HIV treatment, maternal health, and infant feeding guidelines, readers are encouraged to follow reputable health organizations and engage in conversations with medical professionals. Sharing accurate information helps combat stigma and supports informed decision-making in communities worldwide.